{"certainAgreement":{"otherDetails":"No publication of the study results may be made until publication of the results of the multi-centre study or 2 years after study completion, whichever is the sooner","piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"The AEs reported include all events up to the OS data cut-off. After the PFS data cut-off, AEs were only collected for the olaparib and cross-over groups. The safety profile of these 2 groups at OS was consistent with that at the time of PFS."},"pointOfContact":{"email":"ClinicalTrialTransparency@astrazeneca.com","organization":"AstraZeneca","phone":"+44 7884 735492","title":"Paula del Rosario"}}